MAD2L1BP

Across TCGA pan-cancer cohorts, MAD2L1BP Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated MAD2L1BP data layer compared with 23 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher MAD2L1BP Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated MAD2L1BP expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.

HNSC, COAD, and BLCA are the cancer types where MAD2L1BP Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.098	0.710	<.001	12	view →
COAD	OS	Median	All	0.433	0.873	.001	11	view →
BLCA	OS	Median	III,IV	0.506	0.401	.002	8	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

MAD2L1BP–HNSC (DFS)

Open the HNSC breakdown →